Cargando…

Genome-wide mutational signatures revealed distinct developmental paths for human B cell lymphomas

Both somatic hypermutation (SHM) and class switch recombination (CSR) are initiated by activation-induced cytidine deaminase (AID). Dysregulation of these processes has been linked to B cell lymphomagenesis. Here we performed an in-depth analysis of diffuse large B cell lymphoma (DLBCL) and follicul...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xiaofei, Ren, Weicheng, Liu, Dongbing, Li, Xiaobo, Li, Wei, Wang, Xianhuo, Meng, Fei-Long, Yeap, Leng-Siew, Hou, Yong, Zhu, Shida, Casellas, Rafael, Zhang, Huilai, Wu, Kui, Pan-Hammarström, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7608067/
https://www.ncbi.nlm.nih.gov/pubmed/33136155
http://dx.doi.org/10.1084/jem.20200573
Descripción
Sumario:Both somatic hypermutation (SHM) and class switch recombination (CSR) are initiated by activation-induced cytidine deaminase (AID). Dysregulation of these processes has been linked to B cell lymphomagenesis. Here we performed an in-depth analysis of diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) genomes. We characterized seven genomic mutational signatures, including two B cell tumor-specific signatures, one of which is novel and associated with aberrant SHM. We further identified two major mutational signatures (K1 and K2) of clustered mutations (kataegis) resulting from the activities of AID or error-prone DNA polymerase η, respectively. K1 was associated with the immunoglobulin (Ig) switch region mutations/translocations and the ABC subtype of DLBCL, whereas K2 was related to the Ig variable region mutations and the GCB subtype of DLBCL and FL. Similar patterns were also observed in chronic lymphocytic leukemia subtypes. Thus, alterations associated with aberrant CSR and SHM activities can be linked to distinct developmental paths for different subtypes of B cell lymphomas.